Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.

Baigent C. and Sádaba R., (2023), Eur Heart J

Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.

Baigent C. and Sádaba R., (2023), Eur J Cardiothorac Surg, 64

Empagliflozin in Patients with Chronic Kidney Disease. Reply.

Herrington WG. et al, (2023), N Engl J Med, 388, 2301 - 2302

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

HERRINGTON W. et al, (2023), Kidney International Reports

Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.

Chapman D. et al, (2023), Kidney Int

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Humbert M. et al, (2023), European Respiratory Journal, 61

Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK

Zhou J. et al, (2022), PharmacoEconomics

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study

HERRINGTON W. et al, (2022), Clinical Journal of the American Society of Nephrology

Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.

Gaziano L. et al, (2022), Circulation

Empagliflozin in Patients with Chronic Kidney Disease

HERRINGTON W. et al, (2022), New England Journal of Medicine

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials

HERRINGTON W. et al, (2022), The Lancet

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.

Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 645 - 654

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet (London, England), 400, 832 - 845

Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomized trial.

Wang X. et al, (2022), Eur Heart J Digit Health, 3, 426 - 436

CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.

Kotecha D. et al, (2022), Lancet Digit Health

Determining the Relationship between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights from Genetic Epidemiology

HERRINGTON W. et al, (2022), Hypertension

Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy

BAIGENT C. et al, (2022), The Lancet

Angiotensin receptor blockers and β-blockers in Marfan syndrome: an individual-patient-data meta-analysis of randomised trials

EMBERSON J. et al, (2022), The Lancet

Focused cardiac ultrasound to guide the diagnosis of heart failure in pregnant women in India

NAIR M. et al, (2022), Journal of the American Society of Echocardiography

Harmonization of large-scale, heterogeneous individual participant adverse event data from randomized trials of statin therapy

EMBERSON J. et al, (2022), Clinical Trials

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?